A: There was no difference homeostatic model assessment of β-cell (HOMA-β) in subjects with benign hepatic steatosis (NAFL) compared to those with steatohepatitis (NASH).
B: There was a decline in HOMA-β in subjects with NAFL with higher steatotic grade. No similar trend was observed in subjects with NASH.
C: Advanced fibrosis is associated with an increase in HOMA-β in subjects with nonalcoholic fatty liver disease (NAFLD)